The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19

Maria Sofia Basile(University of Catania), Ferdinando Nicoletti(University of Catania), Paolo Fagone(University of Catania), James A. McCubrey(East Carolina University), Eugenio Cavalli(Centro Neurolesi Bonino Pulejo), Jorge Hernández‐Bello(Universidad de Guadalajara), José Francisco Muñóz-Valle(Universidad de Guadalajara)
Drug Discovery Today
November 8, 2021
10.1016/j.drudis.2021.11.002
Cited by 119

Related Papers

Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
|Aging|2011|707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495